Australian guidelines for the clinical care of people with COVID-19

Published by National COVID-19 Clinical Evidence Taskforce on Sep 16, 2020

Disclaimer

The consortium is seeking NHMRC approval of the guideline under section 14A of the National Health and Medical Research Council Act 1992. As part of the approval process (and for the lifetime of the guidelines), public consultation is required. We welcome your feedback and suggestions. Comments can be submitted via the feedback function under each recommendation in Magic or by emailing guidelines@covid19evidence.net.au.

These clinical guidelines are a general guide to appropriate practice, to be followed subject to the clinician’s judgement and the patient’s preference in each individual case. The guidelines are not intended to be proscriptive. They are designed to provide information to assist decision making and have been informed by the highest quality evidence available at the time of compilation. Accordingly, the parties involved in the development of these guidelines shall have no liability to any users of the information contained in this publication for any loss or damage, cost or expense incurred or arising from reliance on the information contained in this publication.   
 

Sponsors

Development of the Australian guidelines for the clinical care of people with COVID-19 is funded by the Australian Government Department of Health, Victorian Government Department of Health and Human Services, the Ian Potter Foundation and the Walter Cottman Endowment Fund, managed by Equity Trustees

Contact

Abstract

Language

en

PICOS

PICO 1.1

Population
Patients with COVID-19
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 1.1

Population
Patients with COVID-19
Intervention
Aprepitant
Comparator
Standard care
Outcomes

PICO 1.1

Population
People exposed to COVID-19
Intervention
Hydroxychloroquine post-exposure prophylaxis
Comparator
Placebo
Outcomes

PICO 1.1

Population
Patients with COVID-19
Intervention
High-flow nasal oxygen therapy
Comparator
Conventional oxygen therapy
Outcomes

PICO 1.1

Population
Patients with COVID-19 on supplementary oxygen who are not yet intubated
Intervention
Prone positioning
Comparator
No prone positioning
Outcomes

PICO 1.1

Population
People with moderate COVID-19
Intervention
DVT prophylaxis
Comparator
Standard care
Outcomes

PICO 1.1

Population
People with COVID-19 who are taking ACEIs/ARBs
Intervention
Continued use of concomitant ACEIs/ARBs
Comparator
Stopping concomitant ACEIs/ARBs
Outcomes

PICO 1.1

Population
Patients with COVID-19
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 1.2

Population
Remdesivir dosage for COVID-19
Intervention
5 days' treatment
Comparator
Up to 10 days' treatment
Outcomes

PICO 1.2

Population
Special populations with COVID-19
Intervention
Aprepitant
Comparator
Standard care
Outcomes

PICO 1.2

Population
Special populations
Intervention
Hydroxychloroquine post-exposure prophylaxis
Comparator
Placebo
Outcomes

PICO 1.2

Population
Patients with COVID-19
Intervention
High-flow nasal oxygen therapy
Comparator
Conventional oxygen therapy
Outcomes

PICO 1.2

Population
Patients with COVID-19
Intervention
DO NOT USE [COPPO] Proning
Comparator
Not proning
Outcomes

PICO 1.2

Population
Patients with severe or critical COVID-19
Intervention
Increased-dose thromboprophylaxis
Comparator
Conventional treatment
Outcomes

PICO 1.2

Population
Patients with COVID-19 who do not require oxygen
Intervention
Corticosteroids
Comparator
Standard Care
Outcomes

PICO 1.3

Population
OUTDATED People with COVID-19
Intervention
Remdesivir
Comparator
Placebo
Outcomes

PICO 1.3

Population
Children and adolescents with COVID-19
Intervention
High-flow nasal oxygen therapy
Comparator
Conventional oxygen therapy
Outcomes

PICO 1.4

Population
OUTDATED Special populations with COVID-19
Intervention
Remdesivir
Comparator
Placebo
Outcomes

PICO 1.5

Population
OUTDATED Patients with severe COVID-19
Intervention
Remdesivir 5-day treatment
Comparator
Remdesivir 10-day treatment
Outcomes

PICO 1.6

Population
OUTDATED Special populations with severe COVID-19
Intervention
Remdesivir 5-day treatment
Comparator
Remdesivir 10-day treatment
Outcomes

PICO 2.1

Population
Special populations with COVID-19 [adapted from general adult population]
Intervention
Remdesivir
Comparator
Standard care
Outcomes

PICO 2.1

Population
Patients with COVID-19
Intervention
Baloxavir marboxil
Comparator
Standard care
Outcomes

PICO 2.1

Population
Patients with hypoxaemia associated with COVID-19
Intervention
Non-invasive ventilation (helmet or face mask)
Comparator
High-flow nasal oxygen (HFNO) or supplementary oxygen therapy (SOT)
Outcomes

PICO 2.1

Population
Pregnant women with COVID-19
Intervention
(V-V) ECMO
Comparator
Mechanical ventilation or other rescue therapies
Outcomes

PICO 2.1

Population
Pregnant women with COVID-19
Intervention
Caesarean section
Comparator
Vaginal birth
Outcomes

PICO 2.1

Population
Special populations with COVID-19 [adapted from general adult population]
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 2.2

Population
Special populations with COVID-19 [adapted from general adult population]
Intervention
5 days' treatment
Comparator
Up to 10 days' treatment
Outcomes

PICO 2.2

Population
Special populations with COVID-19
Intervention
Baloxavir marboxil
Comparator
Standard care
Outcomes

PICO 2.2

Population
Patients with hypoxaemia associated with COVID-19
Intervention
Non-invasive ventilation (helmet or face mask)
Comparator
High-flow nasal oxygen (HFNO) or supplementary oxygen therapy (SOT)
Outcomes

PICO 2.2

Population
Pregnant women with COVID-19 who do not require oxygen [adapted from general adult population]
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 2.3

Population
OUTDATED Pregnant women with COVID-19 [adapted from general adult population]
Intervention
Remdesivir
Comparator
Placebo
Outcomes

PICO 2.3

Population
Children and adolescents with hypoxaemia associated with COVID-19
Intervention
Non-invasive ventilation (helmet or face mask)
Comparator
High-flow nasal oxygen (HFNO) or supplementary oxygen therapy (SOT)
Outcomes

PICO 2.4

Population
OUTDATED Pregnant women with severe COVID-19 [adapted from general adult population]
Intervention
Remdesivir 5-day treatment
Comparator
Remdesivir 10-day treatment
Outcomes

PICO 3.1

Population
OUTDATED Children and adolescents with COVID-19 [adapted from general adult population]
Intervention
Remdesivir
Comparator
Placebo
Outcomes

PICO 3.1

Population
Patients with COVID-19
Intervention
Hydroxychloroquine
Comparator
Standard Care
Outcomes

PICO 3.1

Population
People with asthma or COPD and COVID-19
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 3.1

Population
Children or adolescents with COVID-19 who do not require oxygen [adapted from general adult population]
Intervention
Corticosteroids
Comparator
Standard care
Outcomes

PICO 3.1

Population
Patients with COVID-19
Intervention
Calcifediol
Comparator
Standard care
Outcomes

PICO 3.2

Population
OUTDATED Children and adolescents with severe COVID-19 [adapted from general adult population]
Intervention
Remdesivir 5-day treatment
Comparator
Remdesivir 10-day treatment
Outcomes

PICO 3.2

Population
OLD Patients with COVID-19
Intervention
Hydroxychloroquine for COVID-19
Comparator
Standard Care
Outcomes

PICO 3.2

Population
Special populations with COVID-19
Intervention
Calcifediol
Comparator
Standard care
Outcomes

PICO 3.3

Population
Special populations with COVID-19
Intervention
Hydroxychloroquine
Comparator
Standard Care
Outcomes

PICO 3.4

Population
OLD Special populations with COVID-19
Intervention
Hydroxychloroquine for COVID-19
Comparator
Standard Care
Outcomes

PICO 4.1

Population
Patients with COVID-19
Intervention
Chloroquine
Comparator
Standard care
Outcomes

PICO 4.1

Population
Patients requiring emergency intubation
Intervention
Videolaryngoscopy
Comparator
Direct laryngoscopy
Outcomes

PICO 4.1

Population
Mechanically ventilated children and adolescents with COVID-19 and persistent ventilator dyssynchrony, the need for ongoing deep sedation, prone ventilation or persistently high plateau pressures
Intervention
Continuous infusion of NMBA
Comparator
No continuous infusion of NMBA
Outcomes

PICO 4.1

Population
Women with COVID-19 who have given birth
Intervention
Skin-to-skin contact
Comparator
No skin-to-skin contact
Outcomes

PICO 4.2

Population
Special populations with COVID-19
Intervention
Chloroquine
Comparator
Standard care
Outcomes

PICO 4.2

Population
Neonates, children and adolescents requiring emergency intubation
Intervention
Videolaryngoscopy
Comparator
Direct laryngoscopy
Outcomes

PICO 5.1

Population
OLD Patients with COVID-19
Intervention
Colchicine
Comparator
Standard care
Outcomes

PICO 5.1

Population
Mechanically ventilated adults with COVID-19 and persistent ventilator dyssynchrony, the need for ongoing deep sedation, prone ventilation or persistently high plateau pressures
Intervention
Continuous infusion of NMBA
Comparator
No continuous infusion of NMBA
Outcomes

PICO 5.1

Population
Newborns of mothers with confirmed COVID-19
Intervention
Breastfeeding or breast milk
Comparator
No breastfeeding or breast milk
Outcomes

PICO 5.2

Population
Patients with COVID-19
Intervention
Colchicine
Comparator
Standard care
Outcomes

PICO 5.2

Population
OLD Pregnant women with COVID-19
Intervention
Exposure of a newborn to breastmilk from mothers with confirmed or suspected COVID-19
Comparator
No exposure of a newborn to breastmilk from mothers with confirmed or suspected COVID-19
Outcomes

PICO 5.3

Population
OLD Special populations with COVID-19
Intervention
Colchicine
Comparator
Standard care
Outcomes

PICO 5.4

Population
Special populations with COVID-19
Intervention
Colchicine
Comparator
Standard care
Outcomes

PICO 6.1

Population
OLD Patients with COVID-19
Intervention
Convalescent plasma
Comparator
Standard care
Outcomes

PICO 6.1

Population
Women with COVID-19 who have given birth
Intervention
Rooming-in
Comparator
No rooming-in
Outcomes

PICO 6.2

Population
OLD Special populations with COVID-19
Intervention
Convalescent plasma
Comparator
Standard care
Outcomes

PICO 6.3

Population
Patients with COVID-19
Intervention
Convalescent plasma
Comparator
Standard care
Outcomes

PICO 6.4

Population
Special populations with COVID-19
Intervention
Convalescent plasma
Comparator
Standard care
Outcomes

PICO 7.1

Population
Darunavir-cobicistat for COVID-19
Intervention
Darunavir-cobicistat
Comparator
Standard care
Outcomes

PICO 7.2

Population
Special populations with COVID-19
Intervention
Darunavir-cobicistat
Comparator
Standard care
Outcomes

PICO 8.1

Population
OLD Patients with COVID-19
Intervention
Favipiravir
Comparator
Standard care
Outcomes

PICO 8.2

Population
Patients with COVID-19
Intervention
Favipiravir
Comparator
Standard care
Outcomes

PICO 8.3

Population
OLD Special populations with COVID-19
Intervention
Favipiravir
Comparator
Standard care
Outcomes

PICO 8.4

Population
Special populations with COVID-19
Intervention
Favipiravir
Comparator
Standard care
Outcomes

PICO 9.1

Population
Patients with COVID-19
Intervention
Human umbilical cord mesenchymal stem cells (hUC-MSCs)
Comparator
Standard care
Outcomes

PICO 9.2

Population
Special populations with COVID-19
Intervention
Human umbilical cord mesenchymal stem cells (hUC-MSCs)
Comparator
Standard care
Outcomes

PICO 10.1

Population
Patients with COVID-19
Intervention
Immunoglobulin plus methylprednisolone
Comparator
Standard care
Outcomes

PICO 10.2

Population
Special populations with COVID-19
Intervention
Immunoglobulin plus methylprednisolone
Comparator
Standard care
Outcomes

PICO 11.1

Population
Patients with COVID-19
Intervention
interferon β-1a
Comparator
Standard care
Outcomes

PICO 11.2

Population
Special populations with COVID-19
Intervention
interferon β-1a
Comparator
Standard care
Outcomes

PICO 12.1

Population
Patients with COVID-19
Intervention
Interferon β-1b
Comparator
Standard care
Outcomes

PICO 13.1

Population
People with COVID-19
Intervention
Interferon gamma
Comparator
Standard care
Outcomes

PICO 13.2

Population
Special populations with COVID-19
Intervention
Interferon gamma
Comparator
Standard care
Outcomes

PICO 14.1

Population
Patients with COVID-19
Intervention
Lopinavir-ritonavir
Comparator
Standard care
Outcomes

PICO 14.2

Population
Special populations with COVID-19
Intervention
Lopinavir-ritonavir
Comparator
Standard care
Outcomes

PICO 14.3

Population
Children or adolescents with COVID-19
Intervention
Lopinavir/ritonavir
Comparator
Standard care
Outcomes

PICO 15.1

Population
Patients with COVID-19
Intervention
Ruxolitinib
Comparator
Placebo
Outcomes

PICO 15.2

Population
Special populations with COVID-19
Intervention
Ruxolitinib
Comparator
Placebo
Outcomes

PICO 16.1

Population
Patients with COVID-19
Intervention
Sofosbuvir + daclatasvir
Comparator
Standard care
Outcomes

PICO 16.2

Population
Special populations with COVID-19
Intervention
Sofosbuvir + daclatasvir
Comparator
Standard care
Outcomes

PICO 17.1

Population
Patients with COVID-19
Intervention
Telmisartan
Comparator
Standard care
Outcomes

PICO 17.2

Population
Special populations with COVID-19
Intervention
Telmisartan
Comparator
Standard care
Outcomes

PICO 18.1

Population
Patients with COVID-19
Intervention
Umifenovir
Comparator
Standard care
Outcomes

PICO 18.2

Population
Special populations with COVID-19
Intervention
Umifenovir
Comparator
Standard care
Outcomes

PICO 19.1

Population
NEW Patients with COVID-19
Intervention
Convalescent plasma
Comparator
Control
Outcomes

PICO 19.2

Population
NEW Patients with COVID-19
Intervention
Azithromycin
Comparator
Standard care
Outcomes